Vulvar Cancer: Histopathologic Considerations and Nuances to Management: Vulvar cancer considerations and nuances.
KeyWords
Journal
Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
received:
01
07
2024
revised:
15
07
2024
accepted:
17
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
Vulvar cancer, though rare, poses significant challenges in diagnosis and treatment due to its histopathological complexities and nuances. This paper reviews key aspects of the management of vulvar cancer, focusing on histopathological diagnosis, margin status interpretation, lymph node involvement assessment, and ongoing clinical trials.
Identifiants
pubmed: 39209108
pii: S1879-8500(24)00207-8
doi: 10.1016/j.prro.2024.07.008
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The following authors have disclosed relationships/activities/interests related to the content of this manuscript: S Bedell: $1000 grant for pilot project involving RNA sequencing machine for pilot project of evolutionary mechanisms in endometrial cancer cell lines - Cleveland Society for Obstetrics and Gynecology (CLESOG). C DeCesaris: Employment at the University of Utah; Breast and Gynecologic Cancers Center IIT Grant – SAVE Trial; UG1 grant funding for the NRG 2024 Winter and Summer meetings. G Suneja: American Brachytherapy Society GYN Brachy School 2024; Radiation Oncology Institute, Vice-President of the Board of Trustees. L Burt: Investigator initiated grants for the Reiki-Brachy trial, Med-RT trial, SAVE in Ghana trial and SRS dose escalation trial; Mock oral board examiner honorarium $750 (March 2023), Mock ACGME review for UC Irvine 12/2022 $1000; Leadership - oral board examiner, themednet deputy editor. D Gaffney: Merck, DSMC Chair.